Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 17/20 | 0.77 |
| ▸ | HTR2A | P28223 | 2/20 | 0.77 |
| ▸ | HTR2C | P28335 | 2/20 | 0.77 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939899 | 0.87 | DYRK1A (1.00) | DYRK1AHTR2AHTR2CHASPIN | |
| SCHEMBL16123585 | 0.87 | DYRK1A (1.00) | DYRK1AHTR2AHTR2CHASPIN | |
| SCHEMBL16123601 | 0.84 | DYRK1A (0.78) | DYRK1AHTR2AHTR2CHASPIN | |
| SCHEMBL30629773 | 0.84 | DYRK1A (0.78) | DYRK1AHTR2AHTR2CHASPIN | |
| SCHEMBL20340616 | 0.84 | DYRK1A (0.88) | DYRK1AHTR2AHTR2CHASPIN | |
| SCHEMBL16102805 | 0.83 | HASPIN (0.94) | DYRK1AHTR2AHTR2CHASPIN | |
| SCHEMBL30663727 | 0.83 | HASPIN (0.94) | DYRK1AHTR2AHTR2CHASPIN | |
| SCHEMBL2217485 | 0.82 | DYRK1A (0.80) | DYRK1AHTR2AHTR2CHASPIN | |
| SCHEMBL17517503 | 0.82 | DYRK1A (0.88) | DYRK1AHTR2AHTR2CHASPIN | |
| SCHEMBL13875060 | 0.82 | HASPIN (0.88) | DYRK1AHTR2AHTR2CHASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | FGF1, FGF2, BMP2 | DYRK1A 4508/4885HTR2A 4576/4885HTR2C 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.